Anbio Biotechnology

NNNN

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
SEC CIK: 0001982708

SEC filings (opens in a new tab)

No open-market purchases or sales by Anbio Biotechnology insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $985.2K in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Anbio Biotechnology changed between Q1 2025 and Q2 2025.

All holders in Q2 2025 All holders in Q1 2025

13F holders of NNNN: Q1 2025 compared with Q2 2025
Measure	Q1 2025	Q2 2025	Change
Holders	3	5	+2
Shares	66.4K	29.6K	−36.8K (−55.5%)
Value	$495.5K	$936.7K	+$441.1K (+89.0%)

New holders (3)

Institutions that held Anbio Biotechnology at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to NNNN in Q2 2025
Institution	Shares	Value	% of portfolio
BNP Paribas Arbitrage, SA	1,261	$39.9K	0.00%
Morgan Stanley	400	$12.7K	0.00%
Wells Fargo & Company	100	$3.17K	0.00%

Sold out (1)

Institutions that held Anbio Biotechnology at the end of Q1 2025 and filed for Q2 2025 without it.

Institutions that sold out of NNNN in Q2 2025
Institution	Shares, Q1 2025	Value, Q1 2025
Marshall Wace, LLP	43,629	$325.5K